Evidence map›Paper›PMID 35759945›Full record

ArticleRedox biology2022

Red blood cell eNOS is cardioprotective in acute myocardial infarction.

Miriam M Cortese-Krott, Tatsiana Suvorava, Francesca Leo, Sophia K Heuser, Anthea LoBue, Junjie Li, Stefanie Becher, Rebekka Schneckmann, Tanu Srivrastava, Ralf Erkens and 8 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Miriam M Cortese-KrottMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; Cardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. Electronic address: Miriam.cortese@hhu.de.
Tatsiana SuvoravaMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; Cardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Francesca LeoMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Sophia K HeuserMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Anthea LoBueMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Junjie LiMyocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Stefanie BecherCardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Rebekka SchneckmannDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich-Heine-University, Germany.
Tanu SrivrastavaDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich-Heine-University, Germany.
Ralf ErkensCardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Georg WolffCardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Joachim P SchmittDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich-Heine-University, Germany.
Maria GrandochDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich-Heine-University, Germany.
Jon O LundbergDepartment of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
John PernowDepartment of Cardiology, Karolinska Institute, Stockholm, Sweden.
Brant E IsaksonRobert M. Berne Cardiovascular Research Center, Department of Molecular Physiology and Biophysics, University of Virginia School of Medicine, Charlottesville, VA, USA.
Eddie WeitzbergDepartment of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Malte KelmCardiovascular Research Laboratory, Department of Cardiology Pneumology and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; CARID, Cardiovascular Research Institute Düsseldorf, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Heinrich Heine University Düsseldorf · DEKarolinska Institutet · SEUniversity of Virginia · US

Funding

Role of Pannexins in Vascular Smooth Muscle CellsP01HL120840 · NHLBI · UNIVERSITY OF VIRGINIA · PI BAYLISS, DOUGLAS A., RAVICHANDRAN, KODI S · 2014 to 2023
$24.0M
NHLBI NIH HHS P01 HL120840
6 · The paper itself

Abstract

Red blood cells (RBCs) were shown to transport and release nitric oxide (NO) bioactivity and carry an endothelial NO synthase (eNOS). However, the pathophysiological significance of RBC eNOS for cardioprotection in vivo is unknown. Here we aimed to analyze the role of RBC eNOS in the regulation of coronary blood flow, cardiac performance, and acute myocardial infarction (AMI) in vivo. To specifically distinguish the role of RBC eNOS from the endothelial cell (EC) eNOS, we generated RBC- and EC-specific knock-out (KO) and knock-in (KI) mice by Cre-induced inactivation or reactivation of eNOS. We found that RBC eNOS KO mice had fully preserved coronary dilatory responses and LV function. Instead, EC eNOS KO mice had a decreased coronary flow response in isolated perfused hearts and an increased LV developed pressure in response to elevated arterial pressure, while stroke volume was preserved. Interestingly, RBC eNOS KO showed a significantly increased infarct size and aggravated LV dysfunction with decreased stroke volume and cardiac output. This is consistent with reduced NO bioavailability and oxygen delivery capacity in RBC eNOS KOs. Crucially, RBC eNOS KI mice had decreased infarct size and preserved LV function after AMI. In contrast, EC eNOS KO and EC eNOS KI had no differences in infarct size or LV dysfunction after AMI, as compared to the controls. These data demonstrate that EC eNOS controls coronary vasodilator function, but does not directly affect infarct size, while RBC eNOS limits infarct size in AMI. Therefore, RBC eNOS signaling may represent a novel target for interventions in ischemia/reperfusion after myocardial infarction.

Indexed as

Myocardial InfarctionMyocardial Reperfusion InjuryAnimalsErythrocytesHeartMiceMice, Inbred C57BLMice, KnockoutNitric OxideNitric Oxide Synthase Type IIIVasodilator AgentsNitric OxideNitric Oxide Synthase Type IIINos3 protein, mouseVasodilator AgentsAcute myocardial infarctionCre/LoxP systemIschemia/reperfusion injuryNitric oxide synthaseRed blood cells

Identifiers

PMID35759945
PMCPMC9241051
OpenAlexW4283121670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.